CBLL at a glance
Ceribell, Inc. (CBLL, SEC CIK 1861107) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Ceribell, Inc. (CBLL) shares worth $225.3 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Parvizi Josef on November 16, 2026 of 25,000 shares at $26.02 per share.
- In the last 90 days, CBLL insiders reported 0 open-market purchases ($0) and 14 open-market sales ($3.6M) on Form 4, a net sale of $3.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $89.1M
- +36.1% vs prior year
- Insiders · 90 days
- 0 buys · 14 sells
- Net −$3.6M
- 13F holders
- 24 funds
- $225.3M · −2 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $29.3M, up 30% YoY from $22.6M, driven by product revenue of $22.2M
- Product revenue, best performer, $22.2M, up 31% YoY versus subscription revenue $7.1M, up 28%
- Gross profit $26.3M versus $19.9M YoY, gross-margin percentages not provided in filing tables
- Operating loss $20.5M versus $14.6M YoY, net loss $21.4M versus $13.5M
- Cash, equivalents and marketable securities $117.5M; nine-month operating cash outflow $45.2M versus $30.0M YoY
Risk Factors
- New QMSR compliance risk triggered by FDA’s February 2, 2026 effective rule, potentially increasing costs and regulatory requirements
- Reimbursement risk changed materially: Clarity’s electrographic-status-epilepticus NTAP expired September 30, 2026
- New-product risk from Delirium Monitor System NTAP, effective October 1, 2026, being temporary and not assuring adoption
- Supply-chain risk from China and Vietnam manufacturing, with tariffs potentially raising costs and disrupting availability
- Liquidity risk: $60.4 million net loss and $280.7 million accumulated deficit for the nine months ended September 30, 2026
AI summary of the CBLL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 fiscal 2026 results announced for quarter ended September 30, 2026
- Press release dated November 3, 2026 contains financial results and investor-relevant operating details
Item EX-99.1: Item EX-99.1
- Q3 revenue $29.3M, up 30% year over year, with product revenue $22.2M and subscription revenue $7.1M
- 747 active accounts and 35 net new customers, supporting durable utilization-led growth
Item EX-99.1: Item EX-99.1
- Q2 revenue $28.1M, up 33%; product revenue $21.2M and subscription revenue $6.9M signal broad adoption
- Gross margin reached 92% versus 88%, supported by Vietnam manufacturing and one-time tariff refunds
Item 2.02: Results of Operations and Financial Condition
- Ceribell announced financial results for the quarter ended June 30, 2026
- Full results and management commentary are contained in Exhibit 99.1, dated August 10, 2026
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from seven to nine directors, creating two new seats
- Burke and Taylor shifted from Class I to Classes II and III, respectively, balancing three directors per class
AI summaries of CBLL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CBLL
Don't miss the next CBLL filing
- Alerts as it files. A push when CBLL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CBLL, by share count.
- Ask anything. An AI agent that reads every CBLL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Parvizi Josef | Sell | Nov 16, 2026 | 25,000 | $26.02 |
| BURKE WILLIAM W | Sell | Nov 12, 2026 | 1,155 | $27.48 |
| BURKE WILLIAM W | Sell | Nov 12, 2026 | 16,845 | $26.58 |
| BURKE WILLIAM W | M | Nov 12, 2026 | 18,000 | - |
| BURKE WILLIAM W | M | Nov 12, 2026 | 18,000 | $4.70 |
| Taylor Joseph Michael | Sell | Nov 9, 2026 | 10,200 | $27.22 |
| Woo Raymond | M | Nov 2, 2026 | 23 | - |
| Woo Raymond | M | Nov 2, 2026 | 4,864 | $3.65 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $65.4M | $89.1M |
| Gross Profit | - | $56.8M | $78.3M |
| Operating Income | - | -$39.7M | -$58.4M |
| Net Income | - | -$40.5M | -$53.4M |
| Gross Margin | - | 86.7% | 87.9% |
| Op. Margin | - | -60.7% | -65.6% |
| Net Margin | - | -61.8% | -60.0% |
| Balance Sheet | |||
| Total Assets | $58.9M | $225.4M | $195.8M |
| Equity | - | $191.2M | $155.3M |
| ROE | - | -21.2% | -34.4% |
| Per Share | |||
| EPS | $-5.56 | $-3.39 | $-1.46 |
| Cash Flow | |||
| Operating CF | - | -$35.0M | -$40.8M |
| CapEx | - | $1.3M | $767K |
Source: XBRL data in Ceribell, Inc. (CBLL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CBLL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $225.3M |
| Q2 2026 | 26 | $276.4M |
| Q1 2026 | 25 | $244.9M |
| Q4 2025 | 21 | $245.5M |
| Q3 2025 | 18 | $126.1M |
| Q2 2025 | 20 | $190.2M |
| Q1 2025 | 14 | $135.5M |
| Q4 2024 | 15 | $187.0M |
- D.E. Shaw & Co+327.6K (+220%)
- Citadel Advisors LLC+263.6K (+135%)
- JPMorgan Chase & Co+255.9K (+74%)
- Vanguard Capital Management LLC+221.6K (+20%)
- BlackRock+177.4K (+9%)
- BNY Mellon−819.4K (-91%)
- Millennium Management−139.4K (-19%)
- Citigroup−36.5K (-45%)
- AQR Capital Management−26.4K (-28%)
- Wells Fargo & Co−16.8K (-66%)
- FMR LLC (Fidelity)−5.69M
- Principal Financial Group−22.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 163 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CBLL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 13, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 4, 2026 | - | - | - |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 2, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 20, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
Related Health Care companies
- AXGN · Axogen, Inc.Electromedical & Electrotherapeutic Apparatus
- BLFS · BIOLIFE SOLUTIONS INCElectromedical & Electrotherapeutic Apparatus
- CV · CapsoVision, IncElectromedical & Electrotherapeutic Apparatus
- CNMD · CONMED CorpElectromedical & Electrotherapeutic Apparatus
- ELMD · Electromed, Inc.Electromedical & Electrotherapeutic Apparatus
- HYPR · Hyperfine IncElectromedical & Electrotherapeutic Apparatus
- ITGR · Integer Holdings CorpElectromedical & Electrotherapeutic Apparatus
- LIVN · LivaNova PLCElectromedical & Electrotherapeutic Apparatus
CBLL SEC filings: frequently asked questions
Are CBLL insiders buying or selling?
In the last 90 days, Ceribell, Inc. (CBLL) officers, directors and 10% owners reported no open-market purchases and 14 open-market sales worth $3.6 million by 7 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CBLL stock?
As of September 30, 2026, the largest Ceribell, Inc. (CBLL) holders among the 13F filers tracked by SignalX were BlackRock ($51.5 million), Vanguard Capital Management LLC ($33.0 million), Franklin Resources ($25.3 million), State Street Corp ($15.3 million), JPMorgan Chase & Co ($14.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CBLL's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Ceribell, Inc. (CBLL) reported revenue of $89.1 million (up 36.1% from FY2024) and a net loss of $53.4 million. Diluted EPS was -$1.46. The figures come from the XBRL data in the 10-K.
What did CBLL report in its latest 8-K?
Ceribell, Inc. (CBLL) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 results announced for quarter ended September 30, 2026.
What are the latest CBLL SEC filings?
Ceribell, Inc. (CBLL) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 17, 2026.
What is CBLL's SEC CIK number?
Ceribell, Inc. (CBLL)'s SEC Central Index Key (CIK) is 1861107. EDGAR lists every CBLL filing under that number.
Ask anything about CBLL
The research agent reads CBLL's filings, financials, insider trades and 13F holders, then answers with sources.